iNtRON Biotechnology, Inc. Logo

iNtRON Biotechnology, Inc.

Develops phage therapeutics and molecular diagnostics to combat infectious diseases.

048530 | KO

Overview

Corporate Details

ISIN(s):
KR7048530000
LEI:
Country:
South Korea
Address:
경기도 성남시 중원구 사기막골로 137 중앙인더스피아 5차 701~704호, 성남시
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

iNtRON Biotechnology, Inc. is a biopharmaceutical company specializing in the development of novel drugs and molecular diagnostics. The company is a recognized leader in bacteriophage and endolysin-based technologies, focusing on creating innovative therapeutics to combat infectious diseases, including antibiotic-resistant super-bacteria. Its core activities encompass the development of 'first-in-class' biopharmaceutical pipelines, such as its PHAGERIA® platform, which targets the gut microbiome. In addition to therapeutics, iNtRON develops and manufactures molecular diagnostic assays and reagents for human and animal diseases, utilizing technologies like real-time PCR. The company aims to be a global R&D leader in the immune and immunotherapeutics market.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-14 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 91.8 KB
2025-08-14 00:00
Interim Report
반기보고서 (2025.06)
Korean 1.4 MB
2025-06-12 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.3 KB
2025-06-12 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 20.1 KB
2025-05-19 00:00
Report Publication Announcement
기업설명회(IR)개최
Korean 7.0 KB
2025-05-15 00:00
Quarterly Report
분기보고서 (2025.03)
Korean 1.3 MB
2025-05-14 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 96.1 KB
2025-04-18 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 96.1 KB
2025-04-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.0 KB
2025-04-09 00:00
Transaction in Own Shares
주요사항보고서(자기주식취득신탁계약해지결정)
Korean 28.0 KB
2025-04-09 00:00
Regulatory News Service
신탁계약해지결과보고서
Korean 20.1 KB
2025-04-09 00:00
Transaction in Own Shares
신탁계약해지결과보고서
Korean 20.8 KB
2025-04-03 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 97.7 KB
2025-03-19 00:00
Post-Annual General Meeting Information
정기주주총회결과
Korean 21.6 KB
2025-03-13 00:00
Major Shareholding Notification
주식등의대량보유상황보고서(일반)
Korean 99.2 KB

Automate Your Workflow. Get a real-time feed of all iNtRON Biotechnology, Inc. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for iNtRON Biotechnology, Inc.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for iNtRON Biotechnology, Inc. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

LISATA THERAPEUTICS, INC. Logo
Oncology firm with a platform for more effective, targeted delivery of anti-cancer drugs.
United States of America
LSTA
LIXTE BIOTECHNOLOGY HOLDINGS, INC. Logo
Developing novel PP2A inhibitors to enhance cancer therapies and overcome treatment resistance.
United States of America
LIXT
Longeveron Inc. Logo
Develops cell therapies for Alzheimer's, aging frailty, and rare infant heart defects.
United States of America
LGVN
Lonza Group AG Logo
A leading CDMO for pharma, biotech & nutrition, providing end-to-end development & manufacturing.
Switzerland
LONN
Lyell Immunopharma, Inc. Logo
Develops durable CAR T-cell therapies for solid tumors & blood cancers by reprogramming T-cells.
United States of America
LYEL
Lyra Therapeutics, Inc. Logo
Developing localized, long-acting therapies for chronic rhinosinusitis (CRS).
United States of America
LYRA
Lytix Biopharma AS Logo
Develops oncolytic peptide immunotherapies that kill cancer and stimulate an anti-tumor response.
Norway
LYTIX
MaaT Pharma Logo
Developing gut microbiome therapies to improve survival for cancer patients.
France
MAAT
Mabion S.A. Logo
Global CDMO providing end-to-end services for developing and manufacturing complex biologic drugs.
Poland
MAB
MACROGENICS INC Logo
Biopharma firm developing innovative antibody-based therapeutics for cancer treatment.
United States of America
MGNX

Talk to a Data Expert

Have a question? We'll get back to you promptly.